PTC Therapeutics said Monday that it would receive a net price of $35,000 annually per patient for deflazacort (Emflaza), the muscular dystrophy drug it acquired from Marathon Pharmaceuticals in April. PTC said the $35,000 net price reflected how much it expected to receive from a typical pediatric patient weighing 25 kilograms, or about 55 pounds. Marathon had ignited a backlash from patient advocates and politicians in February, when it announced a wholesale list price of $89,000 annually for deflazacort after it was approved for sale by FDA. The price was approximately 70 times more than some U.S. patients had been paying to import deflazacort from the United Kingdom. PTC's announcement failed to assuage the concerns of some federal lawmakers who had criticized Marathon's $89,000 list price. "A sale in drug rights does not make Marathon—and now PTC—immune from congressional oversight," said a spokesman for Rep. Robert Aderholt (R-AL).